Steven Cohen's NKTR Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 433,419 shares of Nektar Therapeutics (NKTR) worth $18.32 M, representing 0.02% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Steven Cohen has initiated a new position in NKTR, representing a fresh investment thesis on this company. Largest addition occurred in Q4 2025, adding 309,761 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Nektar Therapeutics (NKTR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nektar Therapeutics (NKTR) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +309,761 | Add 250.50% | 433,419 | $42.28 |
| Q3 2025 | +123,658 | New Buy | 123,658 | $56.90 |
Steven Cohen's Nektar Therapeutics Investment FAQs
Steven Cohen first purchased Nektar Therapeutics (NKTR) in Q3 2025, acquiring 123,658 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Nektar Therapeutics (NKTR) for 2 quarters since Q3 2025.
Steven Cohen's largest addition to Nektar Therapeutics (NKTR) was in Q4 2025, adding 433,419 shares worth $18.32 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 433,419 shares of Nektar Therapeutics (NKTR), valued at approximately $18.32 M.
As of the Q4 2025 filing, Nektar Therapeutics (NKTR) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Nektar Therapeutics (NKTR) was 433,419 shares, as reported at the end of Q4 2025.